Validation of the M.D. Anderson symptom inventory brain tumor module (MDASI-BT)

T. S. Armstrong, T. Mendoza, I. Gring, C. Coco, M. Z. Cohen, L. Eriksen, Ming Ann Hsu, M. R. Gilbert, C. Cleeland

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Background: Symptom occurrence has been shown to predict treatment course and survival in patients with solid tumors. Primary brain tumor (PBT) patients are unique in the occurrence of neurologic symptoms. Currently, no instrument exists that measures both neurologic and cancer-related symptoms. Methods: Patients diagnosed with PBT participated in this study. Data was collected at one point in time and included demographic and clinical factors, and the M.D. Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). The study evaluated the reliability and validity of the MDASI-BT in primary brain tumor patients. Results: Two hundred and one patients participated in this study. Mean symptom severity of items as well as cluster analysis was used to reduce the number of total items to 22 (13 core, 9 brain tumor items). Regression analysis showed more than half (56%) of the variability in symptom severity was explained by brain module items. The MDASI-BT measures six underlying constructs including affective, cognitive, focal neurologic deficit, constitutional, generalized symptom, and a gastrointestinal related factor. The internal consistency (reliability) of the instrument was 0.91. The MDASI-BT was sensitive to disease severity based on performance status (P < 0.001), tumor recurrence (P < 0.01), and mean symptom interference (P < 0.001). Conclusions: The 22 item MDASI-BT demonstrated validity and reliability in patients with PBT. This instrument can be used to identify symptom occurrence throughout the disease trajectory and to evaluate interventions designed for symptom management.

Original languageEnglish (US)
Pages (from-to)27-35
Number of pages9
JournalJournal of Neuro-Oncology
Volume80
Issue number1
DOIs
StatePublished - Oct 1 2006

Fingerprint

Brain Neoplasms
Equipment and Supplies
Neurologic Manifestations
Reproducibility of Results
Neoplasms
Nervous System
Cluster Analysis
Regression Analysis
Demography
Recurrence
Survival
Brain

Keywords

  • Brain tumors
  • Self-report instruments
  • Symptoms

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Armstrong, T. S., Mendoza, T., Gring, I., Coco, C., Cohen, M. Z., Eriksen, L., ... Cleeland, C. (2006). Validation of the M.D. Anderson symptom inventory brain tumor module (MDASI-BT). Journal of Neuro-Oncology, 80(1), 27-35. https://doi.org/10.1007/s11060-006-9135-z

Validation of the M.D. Anderson symptom inventory brain tumor module (MDASI-BT). / Armstrong, T. S.; Mendoza, T.; Gring, I.; Coco, C.; Cohen, M. Z.; Eriksen, L.; Hsu, Ming Ann; Gilbert, M. R.; Cleeland, C.

In: Journal of Neuro-Oncology, Vol. 80, No. 1, 01.10.2006, p. 27-35.

Research output: Contribution to journalArticle

Armstrong, TS, Mendoza, T, Gring, I, Coco, C, Cohen, MZ, Eriksen, L, Hsu, MA, Gilbert, MR & Cleeland, C 2006, 'Validation of the M.D. Anderson symptom inventory brain tumor module (MDASI-BT)', Journal of Neuro-Oncology, vol. 80, no. 1, pp. 27-35. https://doi.org/10.1007/s11060-006-9135-z
Armstrong TS, Mendoza T, Gring I, Coco C, Cohen MZ, Eriksen L et al. Validation of the M.D. Anderson symptom inventory brain tumor module (MDASI-BT). Journal of Neuro-Oncology. 2006 Oct 1;80(1):27-35. https://doi.org/10.1007/s11060-006-9135-z
Armstrong, T. S. ; Mendoza, T. ; Gring, I. ; Coco, C. ; Cohen, M. Z. ; Eriksen, L. ; Hsu, Ming Ann ; Gilbert, M. R. ; Cleeland, C. / Validation of the M.D. Anderson symptom inventory brain tumor module (MDASI-BT). In: Journal of Neuro-Oncology. 2006 ; Vol. 80, No. 1. pp. 27-35.
@article{be7735eecbaa4d9f87e13644e41cb3d1,
title = "Validation of the M.D. Anderson symptom inventory brain tumor module (MDASI-BT)",
abstract = "Background: Symptom occurrence has been shown to predict treatment course and survival in patients with solid tumors. Primary brain tumor (PBT) patients are unique in the occurrence of neurologic symptoms. Currently, no instrument exists that measures both neurologic and cancer-related symptoms. Methods: Patients diagnosed with PBT participated in this study. Data was collected at one point in time and included demographic and clinical factors, and the M.D. Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). The study evaluated the reliability and validity of the MDASI-BT in primary brain tumor patients. Results: Two hundred and one patients participated in this study. Mean symptom severity of items as well as cluster analysis was used to reduce the number of total items to 22 (13 core, 9 brain tumor items). Regression analysis showed more than half (56{\%}) of the variability in symptom severity was explained by brain module items. The MDASI-BT measures six underlying constructs including affective, cognitive, focal neurologic deficit, constitutional, generalized symptom, and a gastrointestinal related factor. The internal consistency (reliability) of the instrument was 0.91. The MDASI-BT was sensitive to disease severity based on performance status (P < 0.001), tumor recurrence (P < 0.01), and mean symptom interference (P < 0.001). Conclusions: The 22 item MDASI-BT demonstrated validity and reliability in patients with PBT. This instrument can be used to identify symptom occurrence throughout the disease trajectory and to evaluate interventions designed for symptom management.",
keywords = "Brain tumors, Self-report instruments, Symptoms",
author = "Armstrong, {T. S.} and T. Mendoza and I. Gring and C. Coco and Cohen, {M. Z.} and L. Eriksen and Hsu, {Ming Ann} and Gilbert, {M. R.} and C. Cleeland",
year = "2006",
month = "10",
day = "1",
doi = "10.1007/s11060-006-9135-z",
language = "English (US)",
volume = "80",
pages = "27--35",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Validation of the M.D. Anderson symptom inventory brain tumor module (MDASI-BT)

AU - Armstrong, T. S.

AU - Mendoza, T.

AU - Gring, I.

AU - Coco, C.

AU - Cohen, M. Z.

AU - Eriksen, L.

AU - Hsu, Ming Ann

AU - Gilbert, M. R.

AU - Cleeland, C.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Background: Symptom occurrence has been shown to predict treatment course and survival in patients with solid tumors. Primary brain tumor (PBT) patients are unique in the occurrence of neurologic symptoms. Currently, no instrument exists that measures both neurologic and cancer-related symptoms. Methods: Patients diagnosed with PBT participated in this study. Data was collected at one point in time and included demographic and clinical factors, and the M.D. Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). The study evaluated the reliability and validity of the MDASI-BT in primary brain tumor patients. Results: Two hundred and one patients participated in this study. Mean symptom severity of items as well as cluster analysis was used to reduce the number of total items to 22 (13 core, 9 brain tumor items). Regression analysis showed more than half (56%) of the variability in symptom severity was explained by brain module items. The MDASI-BT measures six underlying constructs including affective, cognitive, focal neurologic deficit, constitutional, generalized symptom, and a gastrointestinal related factor. The internal consistency (reliability) of the instrument was 0.91. The MDASI-BT was sensitive to disease severity based on performance status (P < 0.001), tumor recurrence (P < 0.01), and mean symptom interference (P < 0.001). Conclusions: The 22 item MDASI-BT demonstrated validity and reliability in patients with PBT. This instrument can be used to identify symptom occurrence throughout the disease trajectory and to evaluate interventions designed for symptom management.

AB - Background: Symptom occurrence has been shown to predict treatment course and survival in patients with solid tumors. Primary brain tumor (PBT) patients are unique in the occurrence of neurologic symptoms. Currently, no instrument exists that measures both neurologic and cancer-related symptoms. Methods: Patients diagnosed with PBT participated in this study. Data was collected at one point in time and included demographic and clinical factors, and the M.D. Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). The study evaluated the reliability and validity of the MDASI-BT in primary brain tumor patients. Results: Two hundred and one patients participated in this study. Mean symptom severity of items as well as cluster analysis was used to reduce the number of total items to 22 (13 core, 9 brain tumor items). Regression analysis showed more than half (56%) of the variability in symptom severity was explained by brain module items. The MDASI-BT measures six underlying constructs including affective, cognitive, focal neurologic deficit, constitutional, generalized symptom, and a gastrointestinal related factor. The internal consistency (reliability) of the instrument was 0.91. The MDASI-BT was sensitive to disease severity based on performance status (P < 0.001), tumor recurrence (P < 0.01), and mean symptom interference (P < 0.001). Conclusions: The 22 item MDASI-BT demonstrated validity and reliability in patients with PBT. This instrument can be used to identify symptom occurrence throughout the disease trajectory and to evaluate interventions designed for symptom management.

KW - Brain tumors

KW - Self-report instruments

KW - Symptoms

UR - http://www.scopus.com/inward/record.url?scp=33749181421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749181421&partnerID=8YFLogxK

U2 - 10.1007/s11060-006-9135-z

DO - 10.1007/s11060-006-9135-z

M3 - Article

C2 - 16598415

AN - SCOPUS:33749181421

VL - 80

SP - 27

EP - 35

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -